Table 1 Clinicopathological characteristics of 85 patients with HCC
From: Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin
Age at surgery (years) | |
Median [range] | 64.0 [18–85] |
Sex ratio (M/F) | 5.1 (71/14) |
Etiology of chronic liver disease, n (%) | |
HCV infection HBV infection Alcohol abuse Hemochromatosis NASH Combined viral hepatitis and alcohol Combined metabolic syndrome and alcohol Undetermined | 21 (24.7) 27 (31.8) 5 (5.9) 2 (2.3) 11 (12.9) 5 (5.9) 8 (9.4) 11 (12.9) |
Advanced fibrosis/cirrhosis, n (%) | 49 (57.6) |
Maximal tumour size, mean ± SD (mm) | 65.2 ± 38.5 |
AFP (≥400 ng/ml), n (%)a | 15 (17.6) |
Multiplicity, n (%) | 18 (21.2) |
Tumour grade | |
Well differentiated, n (%) Moderately differentiated, n (%) Poorly differentiated, n (%) | 21 (24.7) 41 (48.2) 23 (27.0) |
CK19 expression, n (%)b | 17 (20.0) |
Microvascular invasion, n (%) | 40 (47.0) |
Satellite nodules, n (%) | 26 (30.5) |
Recurrence, n (%) | 45 (52.9) |
Recurrence before 2 years, n (%) | 40 (47.1) |
Delay to recurrence (months), median [range] | 7.8 [1–61] |
Overall mortality, n (%) | 29 (34.1) |